摘要
目的观察低分子肝素钙在预防小儿过敏性紫癜肾损害中的作用。方法将85例患儿随机分为治疗组(44例)和对照组(41例),治疗组给予低分子肝素钙60～100U/kg,皮下注射,1日1次,连用2周。结果两组随访时间均为3个月以上。治疗1个月及3个月后治疗组尿微量白蛋白(MALB)、尿α-微球蛋白(α-MG)均显著低于对照组(P均<0.01);治疗组与对照组肾炎发生率分别为17.14%(6/35)和42.86%(12/28),两组差异有显著性意义(χ2=3.875,P<0.05);发生肾炎的时间治疗为发病后(91.5±43.7)d,对照组为发病后(43.9±33.5)d,前者明显晚于后者(t=5.26,P<0.001)。结论肝素能预防或减少紫癜性肾炎的发生,具有显著的肾脏保护作用。
Objective To evaluate the therapeutical effect of low molecular heparin calcium in the prevention of Henoch- Schonlein purpura nephritis （HSPN）. Methods The 85 children with Henoch-Schonlein purpura （HSP） were divided into the treatment group （44 cases） and the control group（41 cases） at random. Low molecular heparin calcium 60- 100 U/kg was injected subcutaneously, once daily, for two weeks in the treatment group. Fundamental treatment of two groups was same in the treatment period. The urinary microalbumin（MALB） and α-microglobulin（α- MG）were assayed at admission, a month and three months after treatment. Results All patients were followed for at least 3 months. The urinary MALB and α- MG were not significantly different at admission and significantly different at a month and three months between two groups, significantly lower in treated group than control group. Nephritis was noted in 12 （42.86%）cases in the control group, whereas only 6 （17. 14% ）cases in the treated group （χ^2 =3. 875, P 〈0. 05）. Nephritis occurred latter in the treatment group [（91.5±43.7）d] than the control group[（43.9±33.5）d]（t=5.26, P 〈 0. 001）. Conclusion Heparin could significantly reduce the incidence of HSPN and has obvious renal protective effect.
出处
《中国药业》
CAS
2009年第3期45-46,共2页
China Pharmaceuticals
关键词
紫癜
过敏性
肝素钙
低分子
肾炎
purpura
Henoch - Schonlen
heparin calcium
low molecule
nephritis
